Voltammetric determination of bisoprolol fumarate in pharmaceutical formulations and urine using single-wall carbon nanotubes modified glassy carbon electrode

Novel Deconvoluted Synchronous Spectrofluorimetric Method For Simultaneous Determination Of Bisoprolol and Atorvastatin As Single or Co-administrated Drugs in Bulk and Plasma; Green Assessment

Atorvastatin and bisoprolol are two medications often prescribed together for the management of cardiovascular disease and to reduce mortality. Through a simple and direct technique based on deconvolution and synchronous of the spectrofluorometric spectra, the innovative method enables simultaneous quantification of bisoprolol and atorvastatin as single or co-formulated dosage forms in bulk and plasma. The method depends on measuring the amplitudes of bisoprolol and atorvastatin at 298 nm and 363 nm directly after deconvolution where the other drug doesn't show interference. The linearity of the method was 0.02-0.5 µg/mL and 0.3-25 µg/mL for bisoprolol and atorvastatin, respectively. LOD and LOQ were 0.004, 0.085 µg/mL and 0.013, 0.259 µg/mL for bisoprolol and atorvastatin respectively. Furthermore, green assessment of the method using Eco-Scale and GAPI scale. The method was precise, economical, simple, smart, time-saving and eco-friendly, which allowed its application in quality control unit and in lab assessment.

First derivative synchronous spectrofluorimetric analysis of bisoprolol fumarate and ivabradine in pharmaceutical and biological matrices. Investigation of the method greenness

A novel, facile, rapid, and precise synchronous spectrofluorimetric method was evolved for the simultaneous estimation of bisoprolol fumarate and ivabradine in dosage forms and biological fluids. The estimation is based on measuring the first derivative of the synchronous fluorescence spectra of ivabradine and bisoprolol fumarate in ethanol at Δλ = 80nm. The peak amplitudes are measured at 234.4 nm (zero-crossing point of ivabradine) and 244.0 nm (zero-crossing point of bisoprolol fumarate) to simultaneously analyse bisoprolol fumarate and ivabradine, respectively. The spectrofluorimetric method was optimized by investigating different solvent systems, pH values, and surfactants. The proposed method was linear over concentration ranges of 30.0-200.0 ng/mL and 30.0-180.0 ng/mL for ivabradine and bisoprolol fumarate, respectively with detection limits of 4.88 and 5.28 ng/ml. The developed method was employed for individual assay of the studied compounds in their pharmaceutical dosage forms with high %recoveries. Moreover, the method was applied to analyse ivabradine and bisoprolol fumarate in spiked human urine with %recoveries of 99.98±1.16 and 99.95±1.96 for ivabradine and bisoprolol fumarate, respectively. The method greenness was also investigated by Analytical GREEnness (AGREE), Analytical Eco-Scale, and Green Analytical Procedure Index (GAPI) metrics, which ensured the eco-friendship of the proposed method.

Bisoprolol: A comprehensive profile

The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appearance, its uses, applications, and methods for the preparation are outlined. The profile contains physicochemical properties of Bisoprolol including pKa value, solubility, X-ray powder diffraction, and methods of analysis (including compendial, electrochemical, spectroscopic, chromatographic and capillary electrophoresis). The study also covers thermal analysis such as differential scanning calorimetry and thermogravimetry of Bisoprolol. Which gives a brief idea of melting point, glass transition as well as differentiation between anhydrous and hydrated forms. In addition to these functional groups and structural confirmation of bisoprolol also presented with the help of Fourier transform infrared spectrometry and nuclear magnetic resonance spectroscopy, respectively. The mass fragmentation pattern of bisoprolol fumarate was reported using the electrospray ionization technique. Some recently reported methods for pharmacokinetic analysis of bisoprolol using high-performance liquid chromatography as well as liquid chromatography-mass spectrometry were also included in the study.

Stability-Indicating RP-HPLC and CE Methods for Simultaneous Determination of Bisoprolol and Perindopril in Pharmaceutical Formulation: A Comparative Study

Two fast, accurate and selective stability-indicating methods were developed and validated for the simultaneous determination of bisoprolol, perindopril and three of their possible degradation products. The first proposed method was a gradient reversed phase-high-performance liquid chromatography (HPLC) method, whereas the second was a capillary electrophoresis method. The structures of the obtained degradation products were elucidated using infrared and mass spectrometry. They were also confirmed to be either a drug impurity in the British Pharmacopoeia or a precursor to such impurity. The linearity for bisoprolol and perindopril was achieved in the range of 1-20 μg mL-1 and 5-30 μg mL-1 for HPLC and capillary electrophoresis methods, respectively. The proposed methods were validated according to the International Conference on Harmonisation guidelines. The HPLC method proved to be more sensitive and succeeded in the quantitative determination of the obtained degradation products. Also, it was able to quantify perindopril impurity up to three times lower than the desired limit set by the British Pharmacopoeia. They were successfully employed in the determination of bisoprolol and perindopril in their combined pharmaceutical formulation.

Electrochemical determination of calcium channel blocker drugs using multiwall carbon nanotube-modified glassy carbon electrode

Background

Calcium channel blockers belonging to the dihydropyridine family have been used as a potent arterial vasodilator in the management of angina and cardiovascular diseases. In the design of glassy carbon electrode coatings for the study of the same, multiwall carbon nanotubes (MWCNT) are favored. They are known for the reduction and oxidation of electroactive species towards cathodic and anodic direction with the simultaneous enhancement of the peak current.

Results

The MWCNT-modified glassy carbon electrode exhibited a sharp anodic peak potential at around at 0.5 V for amlodipine (AMLD) andnimodipine (NIMD), and 0.4 V for felodipine (FELD) in the cyclic voltammograms. The antihypertensive drugs were determined using a simple two-step procedure developed which comprised a preconcentration step followed by the differential pulse stripping voltammetric quantification. Concentration calibrations were linear within the range from 0.01 to 0.3 μg/mL for AMLD and FELD, and 0.025 to 0.3 μg/mL for NIMD.

Conclusion

The lower limit detection (LOD) was found to be very low on modified electrode. The LOD is 0.005 μg/mL for AMLD and FELD, and 0.01 μg/mL for NIMD. The prepared electrode showed an excellent electrocatalytic activity towards the oxidation of antihypertensive drugs leading to a remarked improvement in sensitivity. An electrochemical sensor featuring the MWCNT-modified electrode was applied successfully as the result for the calcium channel blocker determination in pharmaceutical samples.